Clinical trial

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

NCT04122833

Study summary

ClinicalTrials.gov

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Design: OBSERVATIONAL · Status: UNKNOWN · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

OTHER · Unmapped registry intervention Next generation sequencing Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2019-09-30

PhaseN/A

Conditions

Adenocarcinoma of Lungverified · MONDO: lung adenocarcinoma

EGFR Activating Mutationunresolved

Interventions

Next generation sequencingOTHER

Sponsors & collaborators

Konkuk University Medical Centerlead sponsor

Roche Diagnostics GmbHcollaborator

Foundation Medicinecollaborator

Mapped research locations

SeoulSouth Korea2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04122833 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.